Overview
A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.
Background
A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.
Indication
Used primarily to treat Lyme disease, acne, and bronchitis. Also indicated (but rarely used) to treat urinary tract infections, gum disease, malaria, and other bacterial infections such as gonorrhea and chlamydia. One of its other registered uses is the treatment of hyponatremia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.
Associated Conditions
- Relapsing fever caused by Borrelia recurrentis
- Tularemia
- Severe Acne Vulgaris
- Psittacosis
- Urinary Tract Infection
- Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
- Acute Intestinal amebiasis
- Conjunctivitis caused by chlamydia
- Yaws
- Campylobacter Infection
- Rickettsia Infections
- Anthrax
- Listeria infection
- Skin Infections caused by Staphylococcus Aureus
- Chlamydial Infections
- Clostridium Difficile Infection (CDI)
- Brucellosis
- Bartonellosis
- Chlamydia Trachomatis Infection
- Gram-Negative Bacterial Infections
- Plague
- Actinomycosis
- Sexually Transmitted Infections (STIs)
- Cholera (Disorder)
- Necrotizing ulcerative gingivostomatitis
- Respiratory Tract Infections (RTI)
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2016/04/15 | Phase 1 | UNKNOWN | |||
2012/12/20 | Phase 4 | Completed | |||
2009/04/02 | N/A | Withdrawn |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Marlex Pharmaceuticals Inc | 10135-626 | ORAL | 300 mg in 1 1 | 10/5/2016 | |
| Amneal Pharmaceuticals LLC | 65162-554 | ORAL | 150 mg in 1 1 | 5/18/2018 | |
| Epic Pharma, LLC | 42806-144 | ORAL | 300 mg in 1 1 | 11/8/2023 | |
| American Health Packaging | 60687-691 | ORAL | 150 mg in 1 1 | 2/28/2023 | |
| Carilion Materials Management | 68151-0155 | ORAL | 150 mg in 1 1 | 4/1/2010 | |
| American Health Packaging | 60687-705 | ORAL | 300 mg in 1 1 | 2/28/2023 | |
| Amneal Pharmaceuticals LLC | 65162-555 | ORAL | 300 mg in 1 1 | 5/18/2018 | |
| Amneal Pharmaceuticals of New York LLC | 53746-555 | ORAL | 300 mg in 1 1 | 2/16/2023 | |
| PuraCap Laboratories LLC | 24658-711 | ORAL | 300 mg in 1 1 | 1/3/2019 | |
| Amneal Pharmaceuticals of New York LLC | 53746-554 | ORAL | 150 mg in 1 1 | 2/16/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||